Literature DB >> 12761489

Response of Ewing tumor cells to forced and activated p53 expression.

Heinrich Kovar1, Sarka Pospisilova, Gunhild Jug, Dieter Printz, Helmut Gadner.   

Abstract

The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53 mutations. In order to test for functional integrity of this pathway, we have investigated a series of EFT cell lines that differ from each other with respect to their endogenous p53 and INK4A gene status for their response to ectopic p53 expression and to stimulation of endogenous p53 activity by X-ray treatment. Significant interindividual and intratumoral variations in the apoptotic propensity of EFT cell lines to transient expression of ectopic p53 were observed, which was independent of the level of p53 expression. In cell lines with a low apoptotic incidence, apoptosis was delayed and the surviving fraction showed a prolonged growth arrest. Complete resistance to p53-induced apoptosis in two cell lines established from the same patient was associated with a high BCL2/BAX ratio and low levels of APAF1. Sensitivity to X-rays showed a trend towards a higher apoptotic rate in wild-type (wt) p53 expressing than in p53 mutant cells. However, one wt p53-expressing EFT cell line was completely refractory to irradiation-stimulated cell death despite high apoptotic responsiveness to ectopic p53. No difference in Ser15 phosphorylation and the transcriptional activation of p53 targets was observed in wt p53 EFT cell lines irrespective of the induction of cell death or growth arrest. All together, our results demonstrate that despite significant variability in the outcome, cell death or cell cycle arrest, the p53 downstream pathway and the DNA damage signaling pathway are functionally intact in EFT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761489     DOI: 10.1038/sj.onc.1206391

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells.

Authors:  Haley L Peters; Ying Yan; Tara M Nordgren; Christine E Cutucache; Shantaram S Joshi; Joyce C Solheim
Journal:  Cancer Biol Ther       Date:  2013-06-26       Impact factor: 4.742

2.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

3.  EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma.

Authors:  Jozef Ban; Idriss M Bennani-Baiti; Max Kauer; Karl-Ludwig Schaefer; Christopher Poremba; Gunhild Jug; Raphaela Schwentner; Oskar Smrzka; Karin Muehlbacher; Dave N T Aryee; Heinrich Kovar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

4.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

5.  Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines.

Authors:  Rosa Noguera; Isidro Machado; Marta Piqueras; Jose Antonio Lopez-Guerrero; Samuel Navarro; Empar Mayordomo; Antonio Pellin; Antonio Llombart-Bosch
Journal:  Diagn Pathol       Date:  2008-07-15       Impact factor: 2.644

6.  Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.

Authors:  D N T Aryee; S Niedan; J Ban; R Schwentner; K Muehlbacher; M Kauer; R Kofler; H Kovar
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

Review 7.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

8.  Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy.

Authors:  Rosa Simona Pinca; Maria Cristina Manara; Valentina Chiadini; Piero Picci; Cinzia Zucchini; Katia Scotlandi
Journal:  Oncol Rep       Date:  2017-01-20       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.